Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Chief Financial Officer | March 29, 2018 | April 03, 2018 |
| INSMED IncINSM · Entity 3174 | Chief Financial Officer | June 03, 2026 | June 05, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director | August 06, 2026 | August 07, 2026 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | CFO/COO | January 16, 2020 | January 21, 2020 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date March 29, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,670 |
Reported balance
After 2018-03-29 transaction · row 1
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 1,088 · Balance 226,670 F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance.
INSMED Inc
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,082 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Sale · Disposed 2,404 · Balance 69,082 F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2036-04-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
ONCOSEC MEDICAL Inc
Report date January 16, 2020 · Filed January 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,389 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Sale · Disposed 1,351 · Balance 41,389 F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2024 Filed Jan 5, 2024 22:27 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 12,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-000691 · wk-form4_1704493648.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,548 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration. F3 · balance_after: Includes 434 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| December 22, 2023 Filed Dec 22, 2023 21:03 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 13,199 | $30.00 | $395,970.00 |
DisclosureSEC source: 0001628280-23-042628 · wk-form4_1703279004.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,241 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 821 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009739 · form4-06132023_040615.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 17,300 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-23-014856 · doc4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:09 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,610 | $18.47 | $29,736.70 |
DisclosureSEC source: 0001628280-23-018679 · wf-form4_168435416317222.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,619 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:09 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,210 | $19.30 | $42,653.00 |
DisclosureSEC source: 0001628280-23-018679 · wf-form4_168435416317222.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,229 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 2,210 shares sold at prices ranging from $19.29 to $19.32 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock · Derivative | 158,410 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0001628280-23-018160 · wf-form4_168418128865059.xml · derivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,410 Underlying: Common Stock · 158,410 shares Expires 2033-05-11 F4 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 21,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018160 · wf-form4_168418128865059.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,439 F3 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: one third on each anniversary of the date of grant through the third anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2023, for no consideration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 34,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018160 · wf-form4_168418128865059.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,331 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2023, for no consideration. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:08 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,857 | $18.12 | $51,768.84 |
DisclosureSEC source: 0001628280-23-000958 · wf-form4_167355767379058.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,031 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 2,857 shares sold at prices ranging from $18.03 to $18.19 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:17 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 37,760 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001628280-23-000632 · wf-form4_167303980436597.xml · derivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,760 Underlying: Common Stock · 37,760 shares Expires 2033-01-05 F5 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of the grant. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:17 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 5,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-000632 · wf-form4_167303980436597.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,888 F4 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: one third on each anniversary of the date of grant through the third anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 5, 2023, for no consideration. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:17 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 8,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-000632 · wf-form4_167303980436597.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,823 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 5, 2023, for no consideration. F3 · balance_after: Includes 908 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006742 · form4-06172022_040601.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to as a director of the Issuer through the vesting date. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (right to buy) · Derivative | 16,300 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000899243-22-022579 · doc4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 14, 2023, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,433 | $18.51 | $26,524.83 |
DisclosureSEC source: 0001140361-22-019783 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,683 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:12 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 94,960 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001140361-22-019172 · form4.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,960 Underlying: Common Stock · 94,960 shares Expires 2032-05-11 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:12 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 20,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019172 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,116 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2022, for no consideration. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,154 | $25.11 | $28,976.94 |
DisclosureSEC source: 0001140361-22-001602 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,979 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:08 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 62,840 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001140361-22-001165 · form4.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,840 Underlying: Common Stock · 62,840 shares Expires 2032-01-06 F4 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-001165 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,133 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 6, 2022, for no consideration. F3 · balance_after: Includes 772 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:45 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000899243-21-022975 · doc4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2031-06-08 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:07 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 68,640 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001140361-21-017464 · form4.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640 Underlying: Common Stock · 68,640 shares Expires 2031-05-12 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:07 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017464 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,355 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 12, 2021, for no consideration. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:40 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 45,600 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001104659-21-002513 · tm211774-13_4seq1.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 Underlying: Common Stock · 45,600 shares Expires 2031-01-07 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:40 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 9,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-002513 · tm211774-13_4seq1.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,183 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 7, 2021, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| July 08, 2020 Filed Jul 13, 2020 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (right to buy) · Derivative | 12,248 | $0.00 Strike: $8.23 | $0.00 |
DisclosureSEC source: 0000899243-20-019000 · doc4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,248 Underlying: Common Stock · 12,248 shares Expires 2030-07-08 F1 · derivative.exercise_date: On July 8, 2020, the Reporting Person was granted an option to purchase 12,248 shares of common stock. 33% of the shares shall vest on July 8 , 2021 and the remaining shall vest in equal monthly installments over the following 24 months. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:58 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 34,890 | $0.00 Strike: $24.70 | $0.00 |
DisclosureSEC source: 0001104659-20-061852 · a4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,890 Underlying: Common Stock · 34,890 shares Expires 2030-05-12 F1 · derivative.exercise_date: The option becomes exercisable based on the following vesting schedule: twenty-five percent (25%) vests on the first anniversary of the date of grant and twelve and one-half percent (12.5%) vests on each six-month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:09 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 91,640 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001127430-20-000034 · edgar.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,640 Underlying: Common Stock · 91,640 shares Expires 2030-02-03 F1 · derivative.exercise_date: In connection with the appointment of Ms. Bonstein as the Company's Chief Financial Officer, the Company granted Ms. Bonstein an option to purchase a total of 91,640 shares of the Company's common stock. The option becomes exercisable based on the following vesting schedule: twenty-five percent (25%) vest on the first anniversary of the date of grant and twelve and one-half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 16:15 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 1,351 | $2.08 | $2,810.08 |
DisclosureSEC source: 0001493152-20-000866 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,389 F1 · shares: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 1,111 | $2.01 | $2,233.11 |
DisclosureSEC source: 0001493152-19-015722 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,740 F1 · shares: In connection with the vesting of 3,906 RSUs on October 16, 2019, a total of 1,111 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 1,111 | $2.42 | $2,688.62 |
DisclosureSEC source: 0001493152-19-010839 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,851 F1 · shares: In connection with the vesting of 3,906 RSUs on July 16, 2019, a total of 1,111 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 16:53 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 11,102 | $0.60 | $6,662.31 |
DisclosureSEC source: 0001493152-19-005630 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,629 F1 · shares: In connection with the vesting of 39,063 RSUs on April 16, 2019, a total of 11,102 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 20:45 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 13,379 | $0.69 | $9,164.62 |
DisclosureSEC source: 0001493152-19-000773 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,731 F1 · shares: In connection with the vesting of 39,063 RSUs on January 16, 2019, a total of 13,379 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| December 24, 2018 Filed Dec 27, 2018 21:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-18-018025 · ownership.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2028-12-24 F1 · shares: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| September 16, 2018 Filed Oct 18, 2018 18:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 15,405 | $1.58 | $24,339.90 |
DisclosureSEC source: 0001493152-18-014645 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,110 F1 · shares: In connection with the vesting of 39,063 RSUs on October 16, 2018, a total of 15,405 shares were withheld by the Company from such RSUs in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:05 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 135,485 | $1.34 | $181,549.90 |
DisclosureSEC source: 0001493152-18-010156 · ownership.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,515 F3 · shares: In connection with the vesting of 312,500 RSUs on July 16, 2018, a total of 135,485 shares were withheld by the Company from such RSUs in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:05 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantCommon Stock | 625,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010156 · ownership.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 F1 · shares: On July 16, 2018, the reporting person was awarded 625,000 RSUs pursuant to an employment inducement award. 312,500 of the RSUs vested and converted to ONCS stock on July 16, 2018, and the remaining 312,500 RSUs vest in equal quarterly installments over the next two years, such that the award will be fully vested on July 16, 2020. F2 · price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,088 | $1.69 | $1,838.72 |
DisclosureSEC source: 0001493152-18-004692 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,670 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 989 | $1.86 | $1,839.54 |
DisclosureSEC source: 0001493152-18-002791 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,582 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,241 shares of which 252 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 580 | $2.96 | $1,716.80 |
DisclosureSEC source: 0001493152-18-001416 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,593 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 780 shares of which 200 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 5,224 | $3.18 | $16,612.32 |
DisclosureSEC source: 0001493152-18-000115 · form-4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,013 F2 · shares: In connection with the vesting of 12,500 shares on January 2, 2018, a total of 5,224 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $3.13 to $3.23. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price in accordance with the issuer's corporate policies. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 473 | $2.84 | $1,343.32 |
DisclosureSEC source: 0001493152-18-000115 · form-4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,237 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 813 shares of which 340 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 856 | $2.99 | $2,559.44 |
DisclosureSEC source: 0001493152-17-014142 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,764 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,158 shares of which 302 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 06, 2017 Filed Nov 6, 2017 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 3,862 | $3.30 | $12,744.60 |
DisclosureSEC source: 0001493152-17-012496 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,908 F1 · shares: In connection with the vesting of 9,533 shares on November 3, 2017, a total of 3,862 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $3.30 to $3.31. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2017 Filed Nov 2, 2017 17:52 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 12,734 | $3.19 | $40,621.46 |
DisclosureSEC source: 0001493152-17-012357 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,770 F2 · shares: In connection with the vesting of 28,827 shares on November 1, 2017, a total of 12,734 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $3.15 to $3.21. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 100,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001493152-17-012496 · form4.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2027-11-02 F3 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2017 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 2, 2018, one-third on November 2, 2019, and will be fully vested on November 2, 2020. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 17:52 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 379 | $3.40 | $1,288.60 |
DisclosureSEC source: 0001493152-17-012357 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,504 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 679 shares of which 300 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 423 | $4.18 | $1,768.14 |
DisclosureSEC source: 0001493152-17-011141 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,125 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 552 shares of which 129 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 273 | $6.81 | $1,859.13 |
DisclosureSEC source: 0001493152-17-010227 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,702 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 339 shares of which 66 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.